Yancy Clyde W
University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Rev Cardiovasc Med. 2005;6 Suppl 2:S43-57.
Despite advances in therapy and better outcomes for heart failure, this disease remains burdensome in terms of hospitalization costs, quality of life, and mortality. Many treatment strategies are available for heart failure, including medical therapy with agents such as angiotensin-converting enzyme inhibitors, and b-blockers, and device therapy including implantable cardioverter-defibrillators and cardiac resynchronization. However, data now demonstrate that compliance with these evidence-based strategies is well below acceptable thresholds, negatively affecting quality of care. The implementation of guidelines such as those of the American College of Cardiology/American Heart Association and the application of dedicated disease management programs are two mechanisms aimed toward helping physicians construct and adhere to effective treatment regimens for their patients with heart failure.
尽管心力衰竭的治疗取得了进展,患者的预后也有所改善,但这种疾病在住院费用、生活质量和死亡率方面仍然是一个沉重的负担。心力衰竭有多种治疗策略,包括使用血管紧张素转换酶抑制剂和β受体阻滞剂等药物进行药物治疗,以及使用植入式心脏复律除颤器和心脏再同步治疗等器械治疗。然而,目前的数据表明,对这些循证策略的依从性远低于可接受的阈值,对医疗质量产生了负面影响。实施美国心脏病学会/美国心脏协会等组织的指南以及应用专门的疾病管理计划是旨在帮助医生为心力衰竭患者制定并坚持有效治疗方案的两种机制。